Sweden · Delayed Price · Currency is SEK Apotea AB Statistics
Total Valuation
Apotea AB has a market cap or net worth of SEK 7.93 billion. The enterprise value is 8.12 billion.
| Market Cap | 7.93B |
| Enterprise Value | 8.12B |
Important Dates
The next confirmed earnings date is Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | May 27, 2026 |
Share Statistics
Apotea AB has 104.07 million shares outstanding. The number of shares has increased by 0.59% in one year.
| Current Share Class | 104.07M |
| Shares Outstanding | 104.07M |
| Shares Change (YoY) | +0.59% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 7.47% |
| Owned by Institutions (%) | 44.41% |
| Float | 65.98M |
Valuation Ratios
The trailing PE ratio is 32.27 and the forward PE ratio is 23.89.
| PE Ratio | 32.27 |
| Forward PE | 23.89 |
| PS Ratio | 1.04 |
| PB Ratio | 8.23 |
| P/TBV Ratio | 8.78 |
| P/FCF Ratio | 51.73 |
| P/OCF Ratio | 33.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.77, with an EV/FCF ratio of 52.98.
| EV / Earnings | 33.03 |
| EV / Sales | 1.07 |
| EV / EBITDA | 15.77 |
| EV / EBIT | 25.55 |
| EV / FCF | 52.98 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.40 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 0.54 |
| Debt / FCF | 1.82 |
| Interest Coverage | 25.62 |
Financial Efficiency
Return on equity (ROE) is 27.83% and return on invested capital (ROIC) is 21.90%.
| Return on Equity (ROE) | 27.83% |
| Return on Assets (ROA) | 9.45% |
| Return on Invested Capital (ROIC) | 21.90% |
| Return on Capital Employed (ROCE) | 26.91% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 10.31M |
| Profits Per Employee | 333,832 |
| Employee Count | 736 |
| Asset Turnover | 3.61 |
| Inventory Turnover | 8.43 |
Taxes
In the past 12 months, Apotea AB has paid 67.60 million in taxes.
| Income Tax | 67.60M |
| Effective Tax Rate | 21.81% |
Stock Price Statistics
The stock price has decreased by -24.72% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -24.72% |
| 50-Day Moving Average | 74.53 |
| 200-Day Moving Average | 73.23 |
| Relative Strength Index (RSI) | 58.61 |
| Average Volume (20 Days) | 133,767 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Apotea AB had revenue of SEK 7.59 billion and earned 245.70 million in profits. Earnings per share was 2.36.
| Revenue | 7.59B |
| Gross Profit | 1.51B |
| Operating Income | 317.70M |
| Pretax Income | 309.90M |
| Net Income | 245.70M |
| EBITDA | 452.10M |
| EBIT | 317.70M |
| Earnings Per Share (EPS) | 2.36 |
Balance Sheet
The company has 103.50 million in cash and 279.30 million in debt, with a net cash position of -175.80 million or -1.69 per share.
| Cash & Cash Equivalents | 103.50M |
| Total Debt | 279.30M |
| Net Cash | -175.80M |
| Net Cash Per Share | -1.69 |
| Equity (Book Value) | 962.80M |
| Book Value Per Share | 9.10 |
| Working Capital | 417.10M |
Cash Flow
In the last 12 months, operating cash flow was 234.00 million and capital expenditures -80.80 million, giving a free cash flow of 153.20 million.
| Operating Cash Flow | 234.00M |
| Capital Expenditures | -80.80M |
| Depreciation & Amortization | 134.40M |
| Net Borrowing | -57.50M |
| Free Cash Flow | 153.20M |
| FCF Per Share | 1.47 |
Margins
Gross margin is 19.85%, with operating and profit margins of 4.19% and 3.24%.
| Gross Margin | 19.85% |
| Operating Margin | 4.19% |
| Pretax Margin | 4.08% |
| Profit Margin | 3.24% |
| EBITDA Margin | 5.96% |
| EBIT Margin | 4.19% |
| FCF Margin | 2.02% |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.81%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 0.81% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 25.40% |
| Buyback Yield | -0.59% |
| Shareholder Yield | 0.23% |
| Earnings Yield | 3.10% |
| FCF Yield | 1.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Apotea AB is 92.50, which is 21.47% higher than the current price. The consensus rating is "Buy".
| Price Target | 92.50 |
| Price Target Difference | 21.47% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 12.01% |
| EPS Growth Forecast (3Y) | 22.67% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Apotea AB has an Altman Z-Score of 8.77 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.77 |
| Piotroski F-Score | 5 |